Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SCZD2
MCID: SCH085
MIFTS: 33

Schizophrenia 2 (SCZD2)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Schizophrenia 2

About this section

MalaCards integrated aliases for Schizophrenia 2:

Name: Schizophrenia 2 56 12 73 15 71
Sczd2 56 12 73
Schizophrenia Susceptibility Locus, Chromosome 11q-Related 56
Schizophrenia Susceptibility Locus Chromosome 11q-Related 73

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0070078
OMIM 56 603342
MeSH 43 D012559
MedGen 41 C1864010
UMLS 71 C1864010
Sources

Summaries for Schizophrenia 2

About this section
UniProtKB/Swiss-Prot : 73 Schizophrenia 2: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

MalaCards based summary : Schizophrenia 2, also known as sczd2, is related to schizophrenia 1 and schizophrenia. An important gene associated with Schizophrenia 2 is SCZD2 (Schizophrenia Disorder 2). The drugs Zinc and insulin have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and cerebellum.

Disease Ontology : 12 A schizophrenia that has material basis in an autosomal dominant mutation of SCZD2 on chromosome 11q14-q21.

More information from OMIM: 603342
Sources

Related Diseases for Schizophrenia 2

About this section

Diseases in the Schizophrenia family:

Schizophrenia 1 Schizophrenia 3
Schizophrenia 4 Schizophrenia 6
Schizophrenia 5 Schizophrenia 7
Schizophrenia 8 Schizophrenia 2
Schizophrenia 9 Schizophrenia 10
Schizophrenia 11 Schizophrenia 12
Schizophrenia 14 Schizophrenia 13
Schizophrenia 15 Schizophrenia 16
Schizophrenia 18 Schizophrenia 19
Early-Onset Schizophrenia

Diseases related to Schizophrenia 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 1 29.4 TSNAX-DISC1 DISC1
2 schizophrenia 29.0 TSNAX-DISC1 SCZD2 PRODH DISC2 DISC1 CNP
3 phobia, specific 10.1 PRODH DISC2
4 delusional disorder 10.0 PRODH DISC1
5 cyclothymic disorder 10.0 DISC1FP1 DISC1
6 schizophreniform disorder 10.0 PRODH DISC1
7 schizotypal personality disorder 9.9 PRODH DISC1
8 schizoaffective disorder 9.8 PRODH DISC2 DISC1
9 mental depression 9.8 PRODH DISC1
10 mood disorder 9.8 PRODH DISC2 DISC1
11 major affective disorder 1 9.7
12 tardive dyskinesia 9.7
13 psychotic disorder 9.7
14 borna disease 9.7
15 glycine encephalopathy 9.5 PRODH LIPT2

Graphical network of the top 20 diseases related to Schizophrenia 2:



Diseases related to Schizophrenia 2
Sources

Symptoms & Phenotypes for Schizophrenia 2

About this section

Clinical features from OMIM:

603342
Sources

Drugs & Therapeutics for Schizophrenia 2

About this section

Drugs for Schizophrenia 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2 insulin Phase 4
3 Insulin, Globin Zinc Phase 4
4 Hypoglycemic Agents Phase 4
5
Fluphenazine Approved Phase 3 69-23-8 3372
6
Haloperidol Approved Phase 3 52-86-8 3559
7
Asenapine Approved Phase 3 85650-56-2, 65576-45-6 3001386
8
Cariprazine Approved, Investigational Phase 3 839712-12-8 11154555
9
Clozapine Approved Phase 3 5786-21-0 2818
10
Kynurenic acid Investigational Phase 2, Phase 3 492-27-3 3845
11 Omega 3 Fatty Acid Phase 2, Phase 3
12 Fluphenazine depot Phase 3
13 Fluphenazine enanthate Phase 3
14 Quetiapine Fumarate Phase 3 111974-72-2
15 Haloperidol decanoate Phase 3
16 Antiemetics Phase 3
17 Gastrointestinal Agents Phase 3
18 Autonomic Agents Phase 3
19 Antidepressive Agents Phase 2, Phase 3
20 Antipsychotic Agents Phase 3
21 Tranquilizing Agents Phase 3
22 Psychotropic Drugs Phase 3
23 Serotonin Agents Phase 3
24 Central Nervous System Depressants Phase 3
25 Serotonin Antagonists Phase 3
26 GABA Agents Phase 3
27 Atomoxetine Hydrochloride Phase 3
28 Adrenergic Agents Phase 3
29
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
30
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
31
Galantamine Approved Phase 2 357-70-0 9651
32
Levodopa Approved Phase 2 59-92-7 6047
33
Carbidopa Approved Phase 2 28860-95-9 34359
34
Icodextrin Approved, Investigational Phase 2 337376-15-5
35
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
36
Polyestradiol phosphate Approved Phase 2 28014-46-2
37 Oxytocics Phase 2
38 Nootropic Agents Phase 2
39 Cholinesterase Inhibitors Phase 2
40 Immunologic Factors Phase 2
41 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2
42 Antiparkinson Agents Phase 2
43 Dihydroxyphenylalanine Phase 2
44 Carbidopa, levodopa drug combination Phase 2
45 Adjuvants, Immunologic Phase 2
46 Estrogens Phase 2
47 Contraceptive Agents Phase 2
48 Estradiol 17 beta-cypionate Phase 2
49 Hormone Antagonists Phase 2
50 Estradiol 3-benzoate Phase 2

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine Unknown status NCT02286206 Phase 4 Clozapine
2 Intranasal Insulin Treatment in Patients With Schizophrenia Completed NCT00575666 Phase 4 Insulin or Placebo
3 Safety and Tolerability of Varenicline When Used for Smoking Cessation/Reduction in Individuals With Severe and Persistent Mental Illness: An Open Label Pilot Trial Withdrawn NCT00702793 Phase 4 Varenicline
4 Ethyl-EPA Treatment of Prodromal Patients Completed NCT00634361 Phase 2, Phase 3 ethyl-eicosapentaenoic acid
5 New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia Completed NCT00161018 Phase 3 Quetiapine, Risperidone, Fluphenazine
6 A Multicenter, Randomized, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of Asenapine Using Haloperidol Positive Control in Subjects Who Complete Protocol 041023 [NCT00156104] Completed NCT00156065 Phase 3 Haloperidol;Asenapine;Asenapine
7 A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia Recruiting NCT03593213 Phase 3 Cariprazine;Placebo
8 Neuroimaging of Tryptophan Challenge in People With Schizophrenia and Healthy Controls Active, not recruiting NCT02067975 Phase 2, Phase 3 Tryptophan;Placebo
9 Correlation of Phenotype, Genotype and Clinical Efficacy/Toxicity of Clozapine Augmented by Atomoxetine for Treatment Refractory Schizophrenia (CAPG Study) Terminated NCT00216281 Phase 3 Clozapine augmented with atomoxetine up to 40 mg or placebo
10 Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study to Compare the Effectiveness of Brexpiprazole to That of Risperidone in Adult Patients With Schizophrenia Withdrawn NCT02758067 Phase 3 brexpiprazole;risperidone
11 A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder Unknown status NCT01598623 Phase 2 Oxytocin
12 Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia Completed NCT01012167 Phase 2 Oxytocin;Galantamine
13 Augmentation of Antipsychotics With L-Dopa (Sinemet) Completed NCT01636037 Phase 2 levodopa/carbidopa (generic version of Sinemet)
14 Multisite Double-Blind Randomized Controlled Study of Estradiol Plus Antipsychotic Versus Placebo Plus Antipsychotic in the Treatment of Psychotic Symptoms in Women With Schizophrenia Completed NCT00357006 Phase 2 Estradiol;Estradiol
15 Relationships of One-carbon Cycle Pathway With Psychopathology and Metabolic Abnormalities in Patients With Schizophrenia and Potential Intervention Strategy With Folic Acid and Vitamin B12 Unknown status NCT02916121
16 Shiatsu Adjuvant Therapy And Placebo For Schizophrenia:a Double Blind Study Unknown status NCT00788970
17 Cognitive Remediation for Perceptual Deficits in Schizophrenia Unknown status NCT02337439
18 Dialectical Behavioral Therapy (DBT) Based Skills Group for Children With Emotional Dysregulation and Their Parents Unknown status NCT01299740
19 Effect of rTMS Over the Medial Cerebellum on Negative Symptoms and Cognitive Dysmetria in Subjects With Treatment Refractory Schizophrenia Unknown status NCT02242578
20 A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES) Unknown status NCT00173069
21 A Study on Risk Mutations of Vulnerability Genes of Schizophrenia Unknown status NCT00155207
22 Art Therapy for Symptom Reduction in Acute Schizophrenia - a Randomised Controlled Trial (Kunsttherapie Zur Symptomreduktion Bei Akuter Schizophrenie - Eine Randomisierte Kontrollierte Pilotstudie) Completed NCT01622166
23 Prevalence of and Factors Associated With Metabolic Syndrome in Patients With Schizophrenia Completed NCT01587521
24 A Genetic Linkage Study of Schizophrenia Completed NCT00155688
25 Effects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia Completed NCT02568709 Early Phase 1 Oxytocin;Saline Nasal Spray
26 Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia Completed NCT00770237
27 The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong: an Open Label Randomized Controlled Trial Completed NCT02435784
28 2-Way Pagers to Improve Schizophrenia Medication Adherence Completed NCT00392236
29 Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia Completed NCT02775864 Antipsychotic;Antidepressant;Benzodiazepine;Mood stabilizer
30 The Impact of Yoga Supplementation on Cognitive Function Among Indian Outpatients With Schizophrenia Completed NCT01879709
31 Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects Completed NCT02575209
32 Implementing Patient-Centered Decision Support for Mental Health Completed NCT02183844
33 Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence Completed NCT01037075
34 Brain Circuits in Schizophrenia and Smoking Completed NCT01369966
35 Implementing Effective, Collaborative Care for Schizophrenia Completed NCT00137280
36 A Positional Cloning Study on Schizophrenia Completed NCT00155649
37 Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios Completed NCT00155506
38 A 12-weeks Study to Evaluate the Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of First Episode Schizophrenia Recruiting NCT03379597 Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
39 Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms on Schizophrenia: Controlled, Randomised, Double Blind Trial Not yet recruiting NCT03284138
40 A Study on Etiological Factors of Schizophrenia Terminated NCT00155636

Search NIH Clinical Center for Schizophrenia 2

Sources

Genetic Tests for Schizophrenia 2

About this section
Sources

Anatomical Context for Schizophrenia 2

About this section

MalaCards organs/tissues related to Schizophrenia 2:

40
Brain, Cortex, Cerebellum, Testes, Prefrontal Cortex, Eye, Placenta
Sources

Publications for Schizophrenia 2

About this section

Articles related to Schizophrenia 2:

(show top 50) (show all 226)
# Title Authors PMID Year
1
Schizophrenia-associated chromosome 11q21 translocation: identification of flanking markers and development of chromosome 11q fragment hybrids as cloning and mapping resources. 61 56
8383424 1993
2
A genetic association study of chromosome 11q22-24 in two different samples implicates the FXYD6 gene, encoding phosphohippolin, in susceptibility to schizophrenia. 56
17357072 2007
3
Family-based association study of schizophrenia with 444 markers and analysis of a new susceptibility locus mapped to 11q13.3. 56
15108173 2004
4
Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. 56
11179014 2001
5
Genome scan of schizophrenia. 56
9619145 1998
6
Physical mapping of a glutamate receptor gene in relation to a balanced translocation associated with schizophrenia in a large Scottish family. 56
9460801 1997
7
An allelic association study of two polymorphic markers in close proximity to a balanced translocation t(1:11) that co-segregates with mental illness. 56
9460802 1997
8
Linkage results on 11Q21-22 in Eastern Quebec pedigrees densely affected by schizophrenia. 56
8825888 1995
9
A contiguous clone map over 3 Mb on the long arm of chromosome 11 across a balanced translocation associated with schizophrenia. 56
7490076 1995
10
Exclusion of linkage of schizophrenia to the gene for the dopamine D2 receptor (DRD2) and chromosome 11q translocation sites. 56
7480434 1995
11
Genetic linkage analysis of schizophrenia using chromosome 11q13-24 markers in Israeli pedigrees. 56
7485242 1995
12
Direct microdissection and microcloning of a translocation breakpoint region, t(1;11)(q42.2;q21), associated with schizophrenia. 56
7736785 1995
13
Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. 56
8439241 1993
14
A linkage study of chromosome 11q in schizophrenia. 56
8439242 1993
15
Association within a family of a balanced autosomal translocation with major mental illness. 56
1973210 1990
16
A balanced chromosomal translocation partially co-segregating with psychotic illness in a family. 56
2349309 1990
17
Analysis of the expression of BAX, BCL2, BIRC6, CASP3, CASP9 apoptosis genes during the first episode of schizophrenia. 61
32017818 2019
18
HIV, schizophrenia, and all-cause mortality: A population-based cohort study of individuals accessing universal medical care from 1998 to 2012 in British Columbia, Canada. 61
31255392 2019
19
International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis. 61
31054641 2019
20
Mental illness stigma among Pacific Islanders. 61
30716597 2019
21
[Reaction on 'Cariprazine for acute and maintenance treatment of schizophrenia']. 61
31907907 2019
22
Bilateral Calcification of Basal Ganglia in a Patient with Duplication of Both 11q13.1q22.1 and 4q35.2 with New Phenotypic Features. 61
31715598 2019
23
Mental health multimorbidity and poor quality of life in patients with schizophrenia. 61
29709490 2018
24
Associations among domains of self-disturbance in schizophrenia. 61
29913377 2018
25
A review of impaired visual processing and the daily visual world in patients with schizophrenia. 61
30214081 2018
26
Schizophrenia as Potential Trigger for Melanoma Development and Progression! The Psycho-Neuro-Endocrine-Oncology (P.N.E.O) Network! 61
30159073 2018
27
Abnormal brain activation during threatening face processing in schizophrenia: A meta-analysis of functional neuroimaging studies. 61
29153447 2018
28
Multinational comparative cross-sectional survey of views of medical students about acceptable terminology and subgroups in schizophrenia. 61
29880569 2018
29
Electroretinographic anomalies in schizophrenia. 61
29745706 2018
30
Abdominal Vagal Afferents Modulate the Brain Transcriptome and Behaviors Relevant to Schizophrenia. 61
29326171 2018
31
Imaging Violence in Schizophrenia: A Systematic Review and Critical Discussion of the MRI Literature. 61
30083111 2018
32
Sex and Diffusion Tensor Imaging of White Matter in Schizophrenia: A Systematic Review Plus Meta-analysis of the Corpus Callosum. 61
28449132 2018
33
Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders. 61
29796036 2018
34
Comorbid Diagnosis of Psychotic Disorders in Borderline Personality Disorder: Prevalence and Influence on Outcome. 61
29593589 2018
35
Exome Sequencing Identifies TENM4 as a Novel Candidate Gene for Schizophrenia in the SCZD2 Locus at 11q14-21. 61
30745909 2018
36
Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis. 61
28980344 2017
37
Guidelines for the Pharmacotherapy of Schizophrenia in Adults. 61
28703015 2017
38
Identification of the delivery of cognitive behavioural therapy for psychosis (CBTp) using a cross-sectional sample from electronic health records and open-text information in a large UK-based mental health case register. 61
28716789 2017
39
The role of shame in people with a diagnosis of schizophrenia. 61
28105670 2017
40
Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia. 61
27455897 2017
41
Schizophrenia and sleep disorders: links, risks, and management challenges. 61
29033618 2017
42
Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. 61
27926742 2017
43
Schizophrenia Associated with Epileptiform Discharges without Seizures Successfully Treated with Levetiracetam. 61
28228737 2017
44
Aberrant intra-salience network dynamic functional connectivity impairs large-scale network interactions in schizophrenia. 61
27825906 2016
45
What are the top 10 physical activity research questions in schizophrenia? 61
26728764 2016
46
Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia. 61
26630458 2016
47
Cognitive remediation in schizophrenia: A methodological appraisal of systematic reviews and meta-analyses. 61
26828372 2016
48
The search for new biomarkers for cognition in schizophrenia. 61
29114461 2015
49
Psychosocial functioning in relation to symptomatic remission: A longitudinal study of first episode schizophrenia. 61
26647865 2015
50
New Targets for Prevention of Schizophrenia: Is It Time for Interventions in the Premorbid Phase? 61
25925393 2015
Sources

Variations for Schizophrenia 2

About this section
Sources

Expression for Schizophrenia 2

About this section
Search GEO for disease gene expression data for Schizophrenia 2.
Sources

Pathways for Schizophrenia 2

About this section
Sources

GO Terms for Schizophrenia 2

About this section
Sources

Sources for Schizophrenia 2

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....